Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26. https://doi.org/10.3322/canjclin.53.1.5
Griffiths CT. Surgical resection of Tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101–4.
Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial Ovarian cancer: a gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621–7. https://doi.org/10.1200/JCO.2006.10.2517
Johnson RL, Laios A, Jackson D, Nugent D, Orsi NM, Theophilou G, et al. The uncertain benefit of adjuvant chemotherapy in advanced low-grade serous Ovarian cancer and the pivotal role of surgical cytoreduction. J Clin Med. 2021;10:5927. https://doi.org/10.3390/jcm10245927
Chi DS, Eisenhauer EL, Lang J, Huh J, Abu-Rustum NR, Sonoda Y, et al. What is the optimal goal of primary cytoreductive Surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559–64. https://doi.org/10.1016/j.ygyno.2006.03.051
Chi DS, Eisenhauer EL, Zivanovic O, Abu-Rustum NR, Levine DA, Guile MW, et al. Improved progression-free and overall survival in advanced Ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114:26–31. https://doi.org/10.1016/j.ygyno.2009.03.018
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial Ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour Les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–44. https://doi.org/10.1002/cncr.24149
Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking Surgery in advanced, unresected epithelial Ovarian cancer. Obstet Gynecol. 1989;73:61–5.
Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced Ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103:1070–6. https://doi.org/10.1016/j.ygyno.2006.06.025
Coleridge SL, Bryant A, Kehoe S, Morrison J. Chemotherapy versus Surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2019;10:CD005343. https://doi.org/10.1002/14651858.CD005343.pub5
Chi DS, Franklin CC, Levine DA, Akserol F, Sabbatini P, Jarnagin WR, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650–4. https://doi.org/10.1016/j.ygyno.2004.01.029
Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of Tumor volume before Surgery and the cytoreductive outcome on survival for patients with advanced Ovarian cancer: a prospective study. Gynecol Oncol. 2003;90:390–6. https://doi.org/10.1016/s0090-8258(03)00278-6
Barton DP, Adib T, Butler J. Surgical practice of UK gynaecological oncologists in the treatment of primary advanced epithelial Ovarian cancer (PAEOC): a questionnaire survey. Gynecol Oncol. 2013;131:347–51. https://doi.org/10.1016/j.ygyno.2013.08.007
Fotopoulou C, Concin N, Planchamp F, Chiva L, Cina A, Ergonol O, et al. Quality indicators for advanced Ovarian cancer Surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int J Gynecol Cancer. 2020;30:436–40. https://doi.org/10.1136/ijgc-2020-001248
Laios A, Katsenou A, Tan YS, Johnson R, Otify M, Kaufmann A, et al. Feature selection is critical for 2-year prognosis in advanced stage high grade serous Ovarian cancer by using machine learning. Cancer Control. 2021;28:10732748211044678. https://doi.org/10.1177/10732748211044678
Dindo D, Demartines N, Clavien PA. Classification of Surgical Complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae
Mutch DG, Prat J. FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133:401–4. https://doi.org/10.1016/j.ygyno.2014.04.013
Newsham AC, Johnston C, Hall G, Leahy MG, Smith MB, Vikram A, et al. Development of an advanced database for clinical trials integrated with an electronic patient record system. Comput Biol Med. 2011;41:575–86. https://doi.org/10.1016/j.compbiomed.2011.04.014
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.
Nelson G, Bakkum-Gamez J, Kalogera E, Glaser G, Altman A, Meyer LA, et al. Guidelines for perioperative care in gynecologic/oncology: enhanced recovery after Surgery (ERAS) society recommendations-2019 update. Int J Gynecol Cancer. 2019;29:651–68. https://doi.org/10.1136/ijgc-2019-000356
Moran J, Wilson F, Guinan E, McCormick P, Hussey J, Moriarty J. Role of cardiopulmonary exercise testing as a risk assessment method in patients undergoing intra-abdominal Surgery: a systematic review. Br J Anaesth. 2016;116:177–91. https://doi.org/10.1093/bja/aev454
Laios A, De Oliveira Silva RV, Dantas De Freitas DL, Tan YS, Saalmink G, Zubayraeva A, et al. Machine learning-based risk prediction of critical care unit admission for Advanced Stage High Grade Serous Ovarian Cancer patients undergoing cytoreductive Surgery: the Leeds-Natal score. J Clin Med. 2022;11:87. https://doi.org/10.3390/jcm11010087
Höckel M. Laterally extended endopelvic resection (LEER)–principles and practice. Gynecol Oncol. 2008;111:13–7. https://doi.org/10.1016/j.ygyno.2008.07.022
Lopez MJ, Luna-Pérez P. Composite pelvic exenteration: is it worthwhile? Ann Surg Oncol. 2004;11:27–33. https://doi.org/10.1007/BF02524342
Fotopoulou C, Planchamp F, Aytulu T, Chiva L, Cina A, Ergönül Ö, et al. European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced Ovarian cancer patients undergoing debulking Surgery. Int J Gynecol Cancer. 2021;31:1199–206. https://doi.org/10.1136/ijgc-2021-002951
Laios A, Kalampokis E, Johnson R, Thangavelu A, Tarabanis C, Nugent D, et al. Explainable Artificial Intelligence for Prediction of Complete Surgical Cytoreduction in Advanced-Stage Epithelial Ovarian Cancer. J Pers Med. 2022;12:607. https://doi.org/10.3390/jpm12040607
Sugarbaker PH. Cytoreductive Surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol. 2001;27:239–43. https://doi.org/10.1053/ejso.2000.1038
Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for Ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107:99–106. https://doi.org/10.1016/j.ygyno.2007.05.032
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74. https://doi.org/10.1007/978-1-4613-1247-5_23
Hamilton CA, Miller A, Miller C, Krivak TC, Farley JH, Chernofsky MR, et al. The impact of Disease distribution on survival in patients with stage III epithelial Ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122:521–6. https://doi.org/10.1016/j.ygyno.2011.04.041
Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, et al. Randomized trial of primary debulking Surgery versus neoadjuvant chemotherapy for advanced epithelial Ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30:1657–64. https://doi.org/10.1136/ijgc-2020-001640
Soleymani Majd H, Ferrari F, Manek S, Gubbala K, Campanile RG, Hardern K, et al. Diaphragmatic peritonectomy vs. full thickness resection with pleurectomy during visceral-peritoneal debulking (VPD) in 100 consecutive patients with stage IIIC-IV Ovarian cancer: a surgical-histological analysis. Gynecol Oncol. 2016;140:430–5. https://doi.org/10.1016/j.ygyno.2015.12.004
Laios A, Kalampokis E, Johnson R, Munot S, Thangavelu A, Hutson R, et al. Development of a novel intra-operative score to record Diseases’ anatomic fingerprints (ANAFI score) for the prediction of complete cytoreduction in Advanced-Stage Ovarian Cancer by using machine learning and explainable Artificial Intelligence. Cancers (Basel). 2023;15:966. https://doi.org/10.3390/cancers15030966
Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary Surgery for advanced Ovarian cancer. Am J Obstet Gynecol. 2007;197:676e1–7. https://doi.org/10.1016/j.ajog.2007.10.495
Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary Surgery or neoadjuvant chemotherapy followed by interval debulking Surgery in advanced Ovarian cancer. Eur J Cancer. 2011;47(Suppl 3):88–92. https://doi.org/10.1016/S0959-8049(11)70152-6
Eggink FA, Koopmans CM, Nijman HW. Surgery for patients with newly diagnosed advanced Ovarian cancer: which patient, when and extent? Curr Opin Oncol. 2017;29:351–8. https://doi.org/10.1097/CCO.0000000000000387
de Jong D, Eijkemans MJ, Lie Fong S, Gerestein CG, Kooi GS, Baalbergen A, et al. Preoperative predictors for residual Tumor after Surgery in patients with ovarian carcinoma. Oncology. 2007;72:293–301. https://doi.org/10.1159/000113051
Laios A, Gryparis A, de Jong D, Hutson R, Theophilou G, Leach C. Predicting complete cytoreduction for advanced Ovarian cancer patients using nearest-neighbor models. J Ovarian Res. 2020;13:117. https://doi.org/10.1186/s13048-020-00700-0
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive Surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59. https://doi.org/10.1200/JCO.2002.20.5.1248
Hughes MJ, Hackney RJ, Lamb PJ, Wigmore SJ, Deans DAC, Skipworth RJE. Prehabilitation before Major Abdominal Surgery: a systematic review and Meta-analysis. World J Surg. 2019;43:1661–8. https://doi.org/10.1007/s00268-019-04950-y
Mulligan KM, Glennon K, Donohoe F, O’Brien Y, Mc Donnell BC, Bartels HC, et al. Multidisciplinary Surgical Approach to increase complete cytoreduction rates for Advanced Ovarian Cancer in a Tertiary Gynecologic Oncology Center. Ann Surg Oncol. 2021;28:4553–60. https://doi.org/10.1245/s10434-020-09494-3
Ross MS, Burriss ME, Winger DG, Edwards RP, Courtney-Brooks M, Boisen MM. Unplanned postoperative intensive care unit admission for Ovarian cancer cytoreduction is associated with significant decrease in overall survival. Gynecol Oncol. 2018;150:306–10. 0.1016/j.ygyno.2018.06.008.
Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, et al. The incidence of major Complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol. 2010;119:38–42. https://doi.org/10.1016/j.ygyno.2010.05.031
Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Shariat SF, et al. In-hospital length of stay after major surgical oncological procedures. Eur J Surg Oncol. 2018;44:969–74. https://doi.org/10.1016/j.ejso.2018.05.001
Searle G, Pounds R, Phillips A, Kehoe A, Balega J, Singh K, et al. Prolonged interruption of chemotherapy in patients undergoing delayed debulking Surgery for advanced high grade serous Ovarian cancer is associated with a worse prognosis. Gynecol Oncol. 2020;158:54–8. https://doi.org/10.1016/j.ygyno.2020.04.048
Vincent C, Moorthy K, Sarker SK, Chang A, Darzi AW. Systems approaches to surgical quality and safety: from concept to measurement. Ann Surg. 2004;239:475–82. https://doi.org/10.1097/01.sla.0000118753.22830.41
Alejandra M, Gertych W, Pomel C, Ferron G, Lusque A, Angeles MA, et al. Adherence to French and ESGO Quality indicators in Ovarian Cancer Surgery: an Ad-Hoc analysis from the prospective Multicentric CURSOC Study. Cancers. 2021;13:1593. https://doi.org/10.3390/cancers13071593
Add Comment